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Lamin A/C gene mutations can be associated with myo-
cardial diseases, usually characterized by dilated cardio-
myopathy and/or arrhythmic disorders. Phenotypic
penetrance is age-related but expression is extremely
heterogeneous, so that muscular and arrhythmic disease
can be present in combination in the same patient, or
one phenotypic manifestation can appear earlier than
the other or even not become overt for a long time per-
iod [1]. From a cardiological point of view, aetiological
diagnosis in dilated cardiomyopathy, and specifically the
diagnosis of cardiolaminopathy, is relevant, since clinical
and prognostic implications as well as specific manage-
ment strategies can be different, particularly with regard
to prevention of sudden cardiac death.
Patients can be diagnosed as being affected by a cardi-
olaminopathy as a result of a cardiological workup per-
formed for symptoms of heart failure or for arrhythmic
events or can be diagnosed incidentally or during family
screening. Family history, physical examination, labora-
tory findings (specifically serum creatine kinase values)
and ECG findings are important “red flags” to diagnose
a cardiolaminopathy. Patients with cardiolaminopathies
may present a wide range of arrhythmic disturbances,
which include either bradyarrhythmias (conduction dis-
turbances and ario-ventricular blocks, sinus node dys-
function, atrial standstill) or tachyarrhyhmias (atrial
fibrillation, ventricular tachycardia and ventricular fibril-
lation), in variable combinations, and with frequent
association with left ventricular dysfunction and heart
failure (Figure 1). The presence and severity of arrhyth-
mic disturbances is usually not related to the presence
and degree of neuromuscular impairment [2-4]. The
most common clinical manifestations are lightheaded-
ness, syncope, palpitations, or even ischemic stroke due
to cardioembolism (in case of atrial fibrillation or atrial
standstill) or sudden death [2-5]. Implantation of a pace-
maker protects form the consequences of bradyarrhyth-
mias, while an implantable cardioverter defibrillator
(ICD) is able to interrupt malignant ventricular tachyar-
rhythmias, thus preventing sudden cardiac death [6].
Biventricular pacing is a form of cardiac stimulation,
referred as cardiac resynchronization therapy (CRT) that
may improve cardiac function in case of heart failure,
low ejection fraction and ventricular dyssynchrony [7].
Clinical decision making has to consider the risk and
benefit of brady- and tachyarrhythmias, taking into
account presence/absence of ventricular dysfunction,
and the decision to implant a cardiac electrical device
(pacemaker, ICD, with/without CRT) should consider
potential risks and benefits (brignole EP). In a multicen-
ter study a series of risk factors emerged as predictors
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Figure 1 Spectrum of cardiac involvement in cardiolaminopathies,
with regard to arrhythmic disturbances and heart failure. Legend:
AV: atrio-ventricular, LV: left ventricular.
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of the occurrence of ventricular tachyarrhythmias (male
gender, non-sustained ventricular tachycardia, left ven-
tricular ejection fraction < 45% and non-missense muta-
tion) and their presence or combination and should
help for the decision to implant an ICD [8].
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